SBRT and hypofractionated CRT showed similar effectiveness and low severe side effects in stage 1 NSCLC treatment. SBRT delivers higher radiation doses in fewer sessions, while hypofractionated CRT ...
Stereotactic body radiotherapy (SBRT) and hypofractionated conventional radiotherapy led to similar tumor control and survival outcomes at 3 years in patients with peripheral and central stage I ...
In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.
In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.
The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...
Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...
The American Society for Radiation Oncology (ASTRO) has issued new guidelines on the appropriate use of stereotactic radiation (SBRT) in early-stage non-small cell lung cancer (NSCLC), now the leading ...
A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...
The primary end points were FISST and local control (LC) rates of lesions that received SBRT. The secondary end point was overall survival (OS) after SBRT. To calculate FISST, event was defined as the ...
SBRT reduced biochemical failure and acute GU toxicity compared with HDR brachytherapy in intermediate-risk prostate cancer. Read more about the findings.
Please provide your email address to receive an email when new articles are posted on . Five-fraction SBRT appeared noninferior to conventional radiotherapy. Grade 2 or higher gastrointestinal adverse ...
Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results